Status:
COMPLETED
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
Lead Sponsor:
Vyne Therapeutics Inc.
Conditions:
Urinary Incontinence
Overactive Bladder
Eligibility:
All Genders
40-74 years
Phase:
PHASE2
Brief Summary
This study is designed to investigate whether a new drug may offer safe and effective treatment for patients with overactive bladder.
Eligibility Criteria
Inclusion
- Patients with predominantly urge incontinence overactive bladder episodes
- Patients must meet minimum eligibility requirements (e.g., average number of micturitions/day) based on screening diary cards
Exclusion
- History of Diabetes insipidus, uncontrolled hyperglycemia or hypercalcemia
- Lower urinary tract symptoms associated with benign prostatic hypertrophy
- Active or current Urinary Tract Infections (UTIs)
- Surgery to correct prolapsed uterus or stress incontinence
Key Trial Info
Start Date :
February 21 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 24 2007
Estimated Enrollment :
557 Patients enrolled
Trial Details
Trial ID
NCT00290563
Start Date
February 21 2006
End Date
September 24 2007
Last Update
May 19 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.